Dopamine antagonists ameliorate the dyskinesias, aggression, and inattention of persons with mental retardation referred to psychiatric clinics

German Journal of Psychiatry

Volumn 4, Issue 1, 2001, Pages 9-16

  Brašic, James Robert ^a,b   Barnett, Jacqueline Y ^b   Zelhof, Richard ^c   Tarpley, Hugh ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c New York State Office of Mental Retardation and Developmental Disabilities   (United States)

Author keywords

Aggression; Attention; Dyskinesias; Mental retardation; Stereotypies; Tics

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; LITHIUM CARBONATE; NEUROLEPTIC AGENT;

ADAPTIVE BEHAVIOR; ADULT; AGGRESSION; AKATHISIA; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BODY MOVEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; FEMALE; HUMAN; MALE; MENTAL DEFICIENCY; MENTAL HOSPITAL; PATIENT REFERRAL; RANK SUM TEST; RISK BENEFIT ANALYSIS; STEREOTYPY; TARDIVE DYSKINESIA; TIC; WITHDRAWAL SYNDROME;

EID: 0035734034     PISSN: 14331055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. A Rating Scale for Drug-Induced Akathisia
2. Movement disorders and cognitive deficits in mental retardation
3. Neurocognitive correlates of dyskinesia in cocaine abstinent adults with mental retardation
4. 2
5. Differentiating myoclonus from tics
6. Pervasive developmental disorder: Asperger syndrome
7. Pervasive developmental disorder: Autism
8. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid
9. Characterization of movement disorders in prepubertal boys with autistic disorder
10. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation
11. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation
12. Clinical assessment of adventitious movements
13. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation
14. Adverse effects of clomipramine
15. Dyskinesias differentiate autistic disorder from catatonia
16. Drugs that block dopamine receptors reduce dyskinesias and aggression and improve attention in individuals with mental retardation
17. Tardive dyskinesia
18. Assuring the quality of the utilization of psychoactive medication by people with mental retardation and developmental disabilities by assessing dosages
19. Neuromotor Assessment and Autistic Disorder
20. PET scanning in autism spectrum disorders
21. Psychoactive Medication Quality Assurance Rating Survey (PQRS)
22. Clinical manifestations of progressive catatonia
23. Progressive catatonia
24. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia
25. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients
26. Asymmetry of neuroleptic-induced rigidity: Development of quantitative methods and clinical correlates
27. Timed Stereotypies Rating Scale
28. Neuropathological investigation of 28 brains from patients with dyskinesia
29. Tardive dyskinesia in the mentally retarded: Comparison of prevalence, risk factors and topography with a schizophrenic population
30. Orofacial dyskinesia in Down's syndrome
31. The significance of brain damage in persistent oral dyskinesia
32. Tardive dyskinesia and dementia
33. The Hillside Akathisia Scale: A new rating instrument for neuroleptic induced akathisia
34. Mood, memory, and motor performance and the severity of tardive dyskinesia
35. Tardive dyskinesia in young mentally retarded individuals
36. Are the effects of chronic neuroleptic therapy different from those occurring on acute administration?
37. The genetics of schizophrenia is the genetics of neurodevelopment
38. Profiles of aggression among psychiatric patients. I. Nature and prevalence
39. Dyskinesia in the mentally handicapped
40. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity
41. Clinical assessment of tic disorder severity
42. Motor and cognitive disturbances in schizophrenic disorders
43. Abnormal involuntary movements and chronic schizophrenic disorders
44. Persistent tardive dyskinesia, caudate atrophy on CT scan and regional blood flow findings in schizophrenia
45. Anosognosia in tardive dyskinesia: "Tardive dysmentia" or "tardive dementia"?
46. Orofacial dyskinesia and senile dementia of the Alzheimer type
47. Neuropsychological impairment in tardive dyskinesia
48. Tardive dyskinesia in psychiatric patients treated with neuroleptics
49. A Children's Global Assessment Scale (CGAS)
50. A Children's Global Assessment Scale (CGAS) (for children 4 to 16 years of age)
51. A rating scale for tardive dyskinesia
52. Memory impairment in schizophrenic patients with tardive dyskinesia
53. Cognitive function and tardive dyskinesia
54. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients
55. Is spontaneous orofacial dyskinesia an artefact due to incomplete drug history?
56. Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: Relationship to tardive dyskinesia
57. Cognitive dysfunction in schizophrenia: Organic vulnerability factor or state marker for tardive dyskinesia?
58. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia: Their association in relation to topography of involuntary movements and criterion of their abnormality
59. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia
60. Cognitive changes associated with tardive dyskinesia
61. The lateralization of tardive dyskinesia
62. In vivo imaging of neurotransmitter systems in neuropsychiatry
63. Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy: Relationship to developmental/intellectual deficit and presence or absence of long-term exposure to neuroleptics